24/7 Wall St. · 3일 전
Research overview
Zoetis Inc. operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.
최근 3개월 추세를 통해 전체 리서치 워크스페이스로 가기 전 단기 구조를 빠르게 파악할 수 있습니다.
Companion-animal spending
Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand.
Osteoarthritis franchise
Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows.
Animal-health innovation
New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.
Product safety
Adverse-event concerns or label changes could slow adoption of important companion-animal products.
Veterinary capacity
Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts.
Livestock volatility
Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.
Zoetis's first-quarter 2026 update reflected continued companion-animal demand, growth-product contributions in pain, parasiticides and dermatology and resilient livestock operations across geographies.
24/7 Wall St. · 3일 전
StockStory · 4일 전
Zacks · 5일 전
Bloomberg · 8일 전
Stocktwits · 11일 전
Keep ZTS in context, run a multi-agent analysis, and monitor thesis changes.
StockStory · 12일 전
Fetched: 2026. 7. 12. AM 12시 0분 0초 UTC
Open original source